CoSense® offers a non‑invasive, rapid breath test that measures end‑tidal carbon monoxide (ETCOc) to quantify hemolysis and neurotoxic risk in newborns with jaundice. By providing results in under five minutes, the monitor enables clinicians to identify high‑risk infants before discharge, reducing readmissions, unnecessary blood draws, and phototherapy use while improving safety and lowering costs.
Funding
Funding not disclosed
Founders
Product
Problem
Newborns at risk of hemolytic hyperbilirubinemia often appear low‑risk at discharge, leading to missed hemolysis, delayed treatment, readmissions, and potential neurotoxicity such as kernicterus. Current screening relies on total serum bilirubin or visual assessment, which cannot reliably detect the rate of bilirubin production caused by hemolysis.
Solution
CoSense® offers a non‑invasive breath test that measures end‑tidal carbon monoxide (ETCOc) to quantify hemolysis and the rate of unconjugated bilirubin production in newborns. The handheld monitor delivers a result in under five minutes, allowing clinicians to identify infants with high hemolytic activity before discharge. By integrating ETCOc data with standard transcutaneous or serum bilirubin measurements, care teams can make more precise decisions about phototherapy, reduce unnecessary blood draws, and lower readmission rates. The technology is based on Sensalyze™ proprietary algorithms that translate breath CO levels into a clinically actionable hemolysis index, aligning with AAP guidelines that endorse ETCOc as the definitive test for hemolysis.
Target Audience
Primary customers are neonatal intensive care units, newborn nurseries, and pediatric hospitals that discharge healthy‑appearing infants and need rapid, objective assessment of hemolysis risk.
Features
- Handheld, battery‑operated monitor that captures a single breath sample and reports ETCOc within 5 minutes
- Sensalyze™ algorithm converts end‑tidal CO concentration to a quantitative hemolysis index correlated with bilirubin production rate
- Seamless workflow integration with existing transcutaneous bilirubin (TcB) or total serum bilirubin (TSB) measurements
- Evidence‑based performance: studies show up to 50 % reduction in repeat blood tests and 20 % reduction in phototherapy utilization
- Cloud‑connected data logging for audit trails, quality control, and optional integration with hospital information systems
- Disposable, single‑use breathing interface to maintain infection control and patient safety